In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Audentes Therapeutics (BOLD), with a price target of $48. The company’s shares closed yesterday at $37.21.
Chattopadhyay said:
“The newly disclosed DMD programs include: (1) vectorized exon skipping product candidates AT702 to treat genotypes amenable to skipping of exons 1 to 5; (2) an undisclosed partnership which adds AT751, and AT753 to treat DMD genotypes amenable to skipping of exons 51 and 53, respectively; and (3) with AT466 Audentes added another preclinical program targeting myotonic dystrophy, which could involve both vectorized RNA knockdown and vectorized exon skipping approaches, with a potential IND during.”
According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.7% and a 42.9% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $43.14, implying a 15.9% upside from current levels. In a report issued on April 17, Leerink Partners also maintained a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Based on Audentes Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $35.59 million. In comparison, last year the company had a GAAP net loss of $25.57 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
